Sleepy Plandai Stock Matches 52-Week High

Marketwired

BALTIMORE, MD--(Marketwired - Aug 15, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that despite the recent market downturn, has Plandaí Biotechnology Inc.'s shares (OTCQB: PLPL) matched its 52-week high earlier this week and appears primed to move substantially higher. The move occurred on nearly four times average daily volume which is a very bullish sign for prospective shareholders and current investors.

At current levels, the stock's daily moving averages (DMA) are quite impressive. For example, the shares are now trading 22% over its 20-day moving average and nearly 300% over its 200-day moving average. The 5-day DMA returns are even more bullish, as Plandaí's shares now trade 11% higher on nearly twice the average daily volume.

Moreover, with relative strength at new highs and DMA volatility at new lows across the board, the stock appears ready to set a new, higher base, led by new shareholders that have purchased shares at these higher prices.

Of course the return to its 52-week high is not driven by technical analysis alone. Company fundamentals, led by a series of pending milestones illustrate that the Company is in its best position in quite some time, thus providing great comfort to shareholders at current levels. For example, Company plans to commence human bioavailability studies to test oral absorption and further human studies to test the efficacy of the product in inducing weight loss. The Company is also poised to begin its first round of in vivo anti-malaria studies, in animals, as a follow up to previously released favorable in vitro studies. Given the type of tests ad studies, early 2014 should see a flurry of trial and test results, which we believe will be overwhelmingly favorable.

Plus, with the start of major commercial production and sales of its flagship product, the total formulated Phytofare™ catechin complex, slated to occur sometime in early-1Q14, this sleepy stock will be generating meaningful revenue as well. All of these events serve to lower the risk profile, add to the already attractive valuation, and serve as a catalyst to drive the PLPL shares to new highs.

Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented pending Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Contact:
Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
rob@goldmanresearch.com
View Comments (0)